Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI and ultrasound join forces to spot muscle wasting in Brain-Injured ICU patients

NCT ID NCT07712198

Knowledge-focused Sponsor: Trabzon Kanuni Education and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests whether artificial intelligence can predict muscle loss (sarcopenia) in intensive care patients with serious brain conditions like stroke, bleeding, or tumors. Researchers will measure thigh muscle thickness with ultrasound and track nutrition markers over the first week. They will then compare how well different AI models—ChatGPT, Gemini, and Claude—can forecast which patients develop muscle wasting. The goal is to see if AI can help doctors identify at-risk patients earlier, without any experimental treatment being given.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could enable early detection of muscle wasting in ICU patients, potentially guiding nutrition and physical therapy to improve recovery.
What could go wrong
This is an observational study with no intervention, so it cannot prove that AI predictions improve outcomes. Results may not apply to all ICU patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult intensive care unit patients aged 18-65 years admitted with intracranial pathologies, including intracerebral hemorrhage, epidural hemorrhage, subdural hemorrhage, subarachnoid hemorrhage, intracranial tumors, and ischemic stroke.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 65 years * Admission to the intensive care unit due to intracranial pathology (intracerebral hemorrhage, epidural hemorrhage, subdural hemorrhage, subarachnoid hemorrhage, intracranial tumors, or ischemic stroke) * Informed consent obtained from the patient or legally authorized representative Exclusion Criteria: * Age \<18 years or \>65 years * Failure to achieve nutritional targets according to ESPEN guidelines * Palliative care or home care patients * Morbid obesity (BMI ≥40 kg/m²) * History of neuromuscular disease * Lower extremity amputation * History of trauma affecting the thigh region * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain neoplasm are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm Hematoma, Epidural, Spinal Hematoma, Subdural intracerebral hemorrhage ischemic stroke Sarcopenia subarachnoid hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intracerebral hemorrhage, subarachnoid hemorrhage, subdural hematoma, epidural hematoma, ischemic stroke, brain neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Trabzon University Faculty of Medicine, Kanuni Training and Research Hospital, Trabzon, 61080

    RECRUITING

    Trabzon, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.